ABSTRACTS COLLECTION

ACNP 59th Annual Meeting: Keyword Index

Keyword ..... **Submission Number(s)**

16p11.2 ..... T81
17-β-estradiol M166
1H MRS 30.2, T122
1H-MRS W45, W128
25CN-NBOH W200
31P magnetic resonance spectroscopy 54
3D genome 25.3
5-HT1A receptors M98
7-dehydrocholesterol T117
7T T69
ABCD study 55, W31
Abstinence T41, T55
Abuse Liability M175, T149
Abuse potential M139, T157, W150
Acamprosate W23
Accelerated aging T10, W130
Acetylcholine 14.2
Acetylcholine esterase inhibitors T150
acoustic startle response 14.4, M75, T91
Actigraphy W43
Activated microglia 43, 43.5
Activity-regulated cytoskeleton-associated protein W55
Acute effects T168, W174
Acute stress 28.1, 34.2, M43, W14
Acute traumatic stress M5
Adaptive behavior M16
Adaptive deep brain stimulation 9, 9.3
Addiction 7.4, 9, 32.2, 34, 34.2, 34.4, 41.3, 44, 47.2, 49.3, 49.5, M47, M147, M167, T124, T172, T175, T193
Addiction circuitry 34.5, M141, W190
Addiction phenotypes 39.1, T195, W161, W181
Adenosine signaling W185
Adenosine triphosphate (ATP) 54.3
ADHD 12, 12.2, M27, T13, W25, W37
Adjunctive therapy M86
ADNI W103
Adolescence 13, 23.3, 39.2, 39.3, M107, M183, T14, T76, T85, T114, W34
Adolescence—critical period 39, M119
Adolescent 12.4, 39.4, M177, T11
Adolescent alcohol M178
Adolescent alcohol exposure 41
Adolescent anxiety 39.4, T164
Adolescent brain cognitive development study T198
Adolescent depression 13.3, M35, M61, M65, T26
Adolescent development M26
Adolescent PTSD M12
Adolescent stress W80
Adolescents M25, M27
Adult hippocampal neurogenesis T29
adverse childhood experiences (ACE) 13.4
Adversity 34
Aerobic exercise 12.4, W169
Affect 44
Affective disorders T21
Affective neuroscience W11
African Americans T10
Ageing 20.2, 31, 31.2, T103, T114
Aggression 11, W182
Aggressive behavior 28
Aging 4, 31.3, T64, T186, W2, W3, W58
Air pollution T77
Alcohol 7.4, 41.2, M152, M167, M173, M186, T72, T161, T176, T179, T181, T188, T194, W146, W165, W172
Alcohol relapse treatment 7.2, 41, M176
Alcohol and substance use disorders 7.3, M160, M176, M191, M192, T42, T164, T172, T195, W181, W182
Alcohol consumption 7.2, 41.5, M178
Alcohol dependence M149
Alcohol drinking 41, M145, M165, T194, W168
Alcohol sensitivity W174
Alcohol use disorder 7, 7.5, 41.4, M149, M159, M163, M169, T43, T55, T183, T186, W147, W157, W165
Alcohol use disorder—treatment M173, T42, T46, T185, T190, W151, W180
Alcohol use disorder metabolism reward T177
Alcohol withdrawal T39, W41, W162
Alcoholic liver disease T185
Alcoholism T175, W156
Alcohol-seeking behavior 41
Allopregnanolone 48.5, T190
Alpha T34
Alpha oscillations W116
Alpha-7 nicotinic acetylcholine receptor M178
Alpha-adrenergic T186
Altitude 3, 3.2
Alzheimer's disease 15, 15.4, T124, T64, W4, W100, W103, W107
AMPA receptors T188
Amphetamine M101, M147, M198, T174, W166
Amygdala 14.5, 38.2, 45.3, M149, T9, T73, T118, W21, W26, W85, W187
Amygdala-hippocampal differences M57
Analgesics M82
Anhedonia 23.5, M56, M77, T158, W97
Animal model 3.2, 4, 46.1, M148, T38
Animal models 40, M85, M195, T105, W29, W105, W177

© The Author(s), under exclusive licence to American College of Neuropsychopharmacology 2020

Animal research T179, W15
Anorexia nervosa M43, T15, T87, T89
Antagonist ligands T49
Anterior cingulate cortex W196
Anterior cingulate cortex (ACC) M131, M163, T67, W26, W68, W193
Anterior insula T16
Antidepressant 5.5, 47.2, M68, M83, M85, T29, W65, W99
Antidepressant response W67
Antidepressant trials W76
Antidepressants M50, M87, W74, W97
Antipsychotic T110, T148
Antipsychotic drug 30.3
Antipsychotic drugs 30, 30.4
Antipsychotic induced weight gain M37
Antipsychotic medication 18
Antipsychotic response M128, W127
Antipsychotic treatment W90
Antipsychotic-induced metabolic dysfunction 30.3
Antipsychotic-induced weight gain T37
Antipsychotic-naïve first-episode schizophrenia 30.2, 42.5
Antipsychotics M112, M114, W128
Anxiety 3.3, 13.2, 23.3, 28.3, 39, M4, M169, T8, T11, T27, T44, T70, T73, T84, T105, T109, T113, W22, W41, W59, W195
Anxiety & PTSD T2, T12, W11, W17
Anxiety circuitry 14.3, M24, T74
Anxiety disorders T6
Anxiety model T28
Apoer2 ..... M87
Apoptosis W54
Arc M6
Arousal 14, 14.2
ASD 26.3, M28, M29, T81
ASD core symptoms T75
Assessment W35
Associative learning T9, T52, T118
Astrocyte 36, 36.5, T51, T64, W152
Astrocyte-neuron interaction T166, W139
Astrocytes M146, T163
Astroglia T90
Astrogliosis 15.2
Attention M40, M198, M201, T57, T156, W4, W53, W152, W195, W196
Attention deficit hyperactivity disorder W51
Atypical antipsychotics M54, T111, W96
Auditory cortex 6.4, T33
Auditory fear conditioning T9, W18, W30
Auditory mismatch negativity T106
Auditory steady-state response M134
Augmentation M83
Autism 26.2, 26.4, M21, M22, M96, T75, W32, W39
Autism behavior inventory T75
Autism spectrum disorder 20.5, 42.3, M23, M31, T11, T78, T197, W26, W101
Autism spectrum disorder and related syndromes M30, T86
Autoantibody T146
Autobiographical memory T200, W85
Autonomic M113
Autonomic nervous system 29.4, 51.3, M14, W88
aV1ation W101
Aversive learning M190
Avoidance M2, M5
Axon guidance molecule genes 39.1
Axons W108
Balloon effort task M126
Balovaptan W101
Bariatric surgery W47
Basal forebrain M155
Basal ganglia 9.4, M101, W190
Basolateral amygdala 48.5, M20, T85, W28
Bayesian inference M199
BDNF M34, M90, T127, W61, W169
BDNF Val66Met W79
Behavior M15, T91, W98
Behavioral flexibility M59, W189
Behavioral genetics W162
Behavioral pharmacology M152, T191, W15, W161
Behavioral phenotyping T105
Behavioral tasks 40, M62
Behavioural neuroscience W15
Belief updating 6.2
BI 1358894 ..... T94
BI 425809 ..... T134, T135
Bifactor M4
Big data T43
Binge drinking T188, W34, W149
Binge eating 9.2
Binge-drinking W182
Bioenergetics 3.2, 54.5
Bioenergetics and insulin resistance 30
Bioinformatics W56
Biological pathway analysis W102
Biomarker 51, M92, T117, W34, W100
Biomarkers 23.4, 51.1, W17
Biomarkers for risk assessment 21, W126
Bipolar depression W90
Bipolar disorder 2.2, 12, 12.3, 12.1, 12.2, 12.4, 25.2, 31, 31.1, 31.2, 31.3, 38.4, 38.5, 45.1, 54.3, 54.4, M54, M58, M60, M64, M67, M71, M124, M200, T92, T97, T103, T110, T141, W54, W58, W72, W87, W90, W125
Bipolar I & II disorder T110, W132
Bipolar I depression T110, W96
Bipolar I disorder W94
Blood pressure W88
Blood-brain-barrier 36.3
BNST M116, M192, T55
Bodily self disturbance 47.4
Body dysmorphic disorder M103
Body mass index M74
Borderline personality disorder M105, T131
Brain 54.5, M16
Brain age 31, T68
Brain aging W5
Brain based markers for depression M91
Brain circuitry M31
Brain connectivity W155

Brain development 2.3, 24.4, 38.2, M30, M31, M33, W133
Brain imaging 12, 42, M19, T76, T87, W47, W67
Brain initiative 19, 19.2
Brain networks 24.1, T59
Brain organoids 52.4
Brain regulation of metabolism 30.4
Brain reward center M148
Brain stress T60
Brain structural connectivity M66, W33
Brain structure M115
Brain ventricular volume M72
Brain-derived neurotrophic factor M20
Brexanolone injection M80, W92
Bumetanide W2
Butyrate W112
Caffeine M27
Calcium imaging 52.3, M102, M146, T19, T119, W19, W139
Cannabidiol M39, M175
Cannabinoids 16, M157, M183, T126
Cannabis M158, M174, M175, T158, T182, W135
Cannabis use T168
Cannabis use disorder M150, M158
Cardiac autonomic tone 3.4
Cardiometabolic risk T152
Cardiovascular disorders 3, 12.4
Cardiovascular physiology W130
Cariprazine M164, T113
Catatonia 45.2, 45.3
Category learning T22
Causal modeling T43
CB2 ..... W38
CBT T128
Cdk5 ..... W7
Cell adhesion molecules T124
Centanafadine W51
Central amygdala M5, M141
Central autonomic network 3.4
Central nucleus of the amygdala M176
Cerebellum M193
Cerebral blood flow W32
c-Fos M6, M44, W22
Chemogenetics 32.2, T194
Chemotherapy-induced peripheral neuropathy T125
Child abuse and neglect M12
Child and adolescent psychiatry 2.3
Child psychopharmacology T198, W35
Childhood trauma 38.2, 51, 51.2, M55, T183
Children 12.3, T12, T79
Children and adolescents 5.3, 38, W35
Choline T122
Cholinergic system W3
Choroid plexus 36, 36.2, T15
CHRNA5 ..... W53
Chronic pain 27, 27.3, M99, T122, W40
Chronic pain treatment W40
Chronic social defeat M77, T18, T115
Chronic stress M94, T17, T85, W66, W99, W115
Chronic unpredictable mild stress W7
Chrono-pharmacology W94
Circadian M106
Circadian rhythms 37.4, 49, 49.5, T159, W54, W94, W125, W163
Circuit T30
Circuit optogenetics 14, 32, 32.2, W18, W190
Circuit-function M100
Circuitry-based approach T17
Circulating mitochondrial DNA 51.3, 54.5, T82
Citalopram M11
Classification 42.3, W50
Claustrum T62
Clinical development M110
Clinical heterogeneity 2.4
Clinical high risk for psychosis 8, W117
Clinical high risk state for psychosis 30.2, W120
Clinical high-risk of psychosis 21, M132
Clinical interventions M36
Clinical neurobiology T172, T195
Clinical psychiatry 17
Clinical subtypes T89
Clinical transition 53
Clinical trial 28.3, M58, M152, W10, W23, W60, W113
Clinical trial design T46
Closed-loop control 19
Closed-loop deep brain stimulation 9.2, 19.5, 46.4
Clozapine M114
Cluster analysis M172
Cluster headache 47.5
CNS depressant drugs M127
CNV T81
Cocaine 36.5, 49.4, M16, M164, M185, T48, T165, T173, T174, W176, W187
Cocaine addiction M151, M154, M156, T180, W142, W145
Cocaine seeking 10.4, W143, W167, W183
Cocaine self-administration M146, T149, T163, T184, W175
Cocaine self-administration and reinstatement 52.2, M157, W167, W169
Cocaine sex differences T163
Cocaine use disorder 25.2
Cognition 24, 44, M40, M113, M182, T35, T65, T122, T157, W116, W123, W154
Cognitive T20
Cognitive control 9.3, W196
Cognitive decline M94
Cognitive deficits 21
Cognitive development 36.4
Cognitive flexibility 9, M155, M195, T80, W200
Cognitive functioning M114, W113
Cognitive impairment M58, T134
Cognitive impairments T138
Cognitive impairment W174
Cognitive neuroscience 6, T80
Cognitive remediation M134
Cognitive training M157, T6
Cognitive/emotional task performance 13.3

Collaborative cross and diversity outbred mice W163
Combat PTSD M7, M9, T72
Common deletion 54.2
Common SNPs T23
Common variant T36
Communication barriers M22
Comorbidity 17, 31, 31.2
Complement factor C4 ..... 43, 43.4, 43.5
Complex I activity 54.2
Compulsion 41.2, M104
Compulsive behavior T188
Compulsive eating W24
Compulsive models of drug use M145
Computational modeling T21, T22
Computational modelling 6.5
Computational models of decision-making 41.3
Computational neuroscience 6, W69
Computational psychiatry M10, W70
Computational reinforcement learning model 39.3
Conditioned fear memory M169
Conditioned place preference M147, W145
Connectivity 43.2, M122
Consciousness T58
Context M177
Contextual cue T3
Contextual fear W30
Continuous performance task W115
Coping 31.1, 34.4
Copy number variants 2
Cortical circuit function 42.3, 45.2, W138
Cortical development 24.1
Cortical excitability M35, M93
Cortical excitation-inihibition balance W93
Cortical GABA T155
Cortical inhibition M93, T153
Cortical plasticity T34
Cortical thickness M159, T102, T133
Corticolimbic W157
Corticospinal tract W170
Corticosterone W79
Corticostriatal networks 9
Cortico-striatal plasticity 48.4
Corticotropin-releasing factor (CRF) M138, T17, W187
Cortisol 27, T7, W165
Cortisol response to stress T96, W156
Court-involved youth M36
COVID-19 ..... 17, 33, 50, M17, M181, M197, T159, W12, W43
Craving 36.2, M173, T44
Creatine M124
Creatine kinase 54.3
Creativity W37
CRF W149
CRH 34.3, M162, W28
CRISPR screens 20.4
CRISPR/Cas9 ..... 20, 20.5, W148
CRISPR/dCas9 ..... W7
Cross species 34
Cross-species translation 22
CRP T72
Cue reactivity M156, M164, T173, T184
Cue reinstatement T187
Cue-exposure T2
Curriculum W44
Cyclooxygenase 15.5
CYP2C19 ..... T100
CYP2D6 ..... T100
Cytochrome P450s T100
Cytokines W129
D1 dopamine receptors W140, W159, W166
D2 dopamine receptor 10.4, T91, W140
D3 receptor T191
D3 receptor partial agonist M164
Dabigatran T94
Daridorexant M137
Data fusion T1
Daytime functioning M137
DBS 9.4
Decision making M16, W192, W193
Deep brain stimulation 9.1, 46, 46.1, 46.2, 46.3, W49, W83
Deep sequencing 2
Default mode network (DMN) 13.4, T62, T200
Defensive and motivated behaviors 27.2, W21
Delay discounting T44
Delta 6.4
Delta opioid receptors 32.5
Delusions M129
Dementia 4, M129, T150
Dendrites M107, W108
Dendritic morphogenesis M193
Dentate gyrus M59
Dependence W150
Depression 2.1, 3.3, 15.3, 19.5, 23.5, 32.3, 36.3, 37, 37.2, 38.4, 38.5, 45.1, 46, 48, 49.3, M17, M55, M62, M63, M68, M69, M71, M72, M78, M79, M83, M131, M200, T20, T29, T92, T98, T101, T102, T107, T113, W27, W50, W63, W64, W66, W75, W83, W86, W87, W88, W89, W97, W99, W199
Depression and anxiety 23, M161, T56, W72
Depression inflammation M92
Depressive symptoms T148
Depressive-like behavior T105
Desmosterol T117
Devaluation M135
Development M32, W30
Developmental T76
Developmental neuropsychiatric disorders T81
Developmental psychopathology 13, 13.1
Developmental trajectory 51.3, T82, W159
Diabetes 23.2
Diabetic peripheral neuropathy T125
Diagnosis W87, W90
Diagnostic prediction 26.4
Dietary supplement W113
Diffusion tensor imaging (DTI) 12.2

Diffusion tractography 46.2
Diffusion weighted imaging 45, T144, W33
Digital phenotyping W36
Dimensional child psychopathology W31
Discrimination 52.1, W27
Disorders of glutamate M124
Distress intolerance M160
Diverse animal models W69
Diversity 1, 35
DLPFC W109
DNA M120
DNA methylation M18, T33, W58
DNA sequencing 2.2
Dopamine 5.2, 6.3, 19.3, 27, 27.2, 30.3, 34.5, M1, M16, M47, M51, M58, M101, M127, M155, M180, M184, M186, M198, T52, T63, T113, T147, T158, T189, W2, W45, W173, W176, W189
Dopamine (D2, D3) receptors 30.3, M184, W166, W171
Dopamine and serotonin 45.1
Dopamine D3 receptors W178
Dopamine D4 receptor T49
Dopamine receptor type 2-expressing striatal medium spiny neuron M201
Dopamine release 52.2
Dopamine3 receptors 52, 52.2
Dopamine-deficient mice M98
Dorsal Hippocampus T65
Dorsal raphe M180
Dorsal striatum T63, W41, W45, W139
Dorsolateral prefrontal cortex T133
Dose response W146
DREADD 49.3
DREADDs W141, W149
Drosophila T181
Drug abuse 39
Drug addiction 49, M179, T48, T162, W176
Drug cues M154, W186
Drug development 21
Drug discovery—new approaches M31
Drug discovery/development T124
Drug discrimination W51
Drug relapse M142, T50, T196
Drug self-administration M142
D-serine M118
DTI M46, M112, T1
Dual orexin receptor antagonist M137, W134, W150
Duration of untreated psychosis T144
Dynamic connectivity 42.2, M103
Dynamic functional connectivity 42.3
Dynamic neural modeling 19.5
Dynamical systems W136
Dynamics M122
Dysregulation T141
Early adolescence 24.4
Early childhood 12.1
Early life adversity M162, T123, W28
Early life stress 23.4, 34.3, M25, M48, M52, M71, M184, M194, T77, T178, W29, W38, W142, W195
Early parental loss T123
Early psychosis M109, M123
Early rearing T83
Eating disorders T88
Ecological momentary assessment T159, W36, W43, W117, W132
Education and training 33, W44
EEG 26, 47.4, T25, T34, T58
EEG biomarkers 6.5, 13.1, 26.2, M7, M196, M198, W4, W93, W116
EEG/ERP electrophysiology M195, T106, W195
EEG-fMRI W136
Efficacy and safety M110
Effort based decision making task T19, W193
Electrical field modeling W10
Electrochemistry M171
Electroconvulsive therapy M78, T92, T104
Electroencephalography T135, W100
Electron microscopy T147
Electronic cigarette (e-cigarette) M181
Electrophysiology 9.1, 49.4, W18, W135
Emotion circuitry T88
Emotion modulation M105, W65
Emotion perception T57
Emotion processing W65
Emotion regulation M60, W191
Emotional dysregulation 31.1
Emotional memory 13.3
Emotional regulation 31, 38, M197
Emotional stress T98
Empathy W158
Endocannabinoid system M19, M180, T132, W172
Endocannabinoids M188
Endogenous opioids 10.1, 10.3, T54
Endogenous retrovirus 25.3
Engram 52, M6, M42
Enkephalin 10.3, 10.4
Entropy T86
Environmental enrichment W56
Epidemiology 2.4, M68
Epigenetic 32.3, 52, 52.1, W142, W180
Epigenetic modification M149
Epigenetic regulation 32
Epigenetics 25.4, M15, M47, M52, M76, M121, T33, T162, T164, T165, T176
Epigenome wide association studies T176
Epilepsy M40, W105
ERK M90
ER-β M166
Escitalopram T24, W93
Esketamine M81
Esketamine nasal spray T93, T95, W62
Estradiol W81
Estrogen receptor M51
Estrogen synthesis T15

Estrous T187
Ethanol W139, W179
Ethics 16
Ethinyl estradiol M166
Event-related potentials M158, T57, T80, W119
EWAS W103
Excitation-inhibition balance T132, W122
Excitatory and inhibitory imbalance hypothesis M93
Excitatory synapses 52.4
Executive function 3.3, T195
Exome sequencing 2.2
Experimental design T20
Experimental medicine 41.5, W100
Explore-exploit dilemma W192
Exposure therapy T128
Exposure-response M129
Externalizing behavior T79
Externalizing disorders 13.1
Extinction T162
Extinction learning W183
Extinction recall 38.2
Extracellular vesicles 51, 51.3
Extrapyramidal symptoms M125
Eye tracking 26, 26.3, T20
Face emotion processing T22
Facial emotional processing T78
Familial risk 38.4, 38.5, M61
Family study 12.1
Fast scan cyclic voltammetry T189
Fatty acids T89
Fear M18, W19
Fear conditioning 36.4, M6, W20, W21
Fear conditioning and extinction T2, T3, T4, T12, W16
Fear extinction 39.2, M86, T14
Fear generalization 52.1, T2
Fear learning M24
Fear-potentiated startle W17
Fecal microbiome transportation M77
Feeding behavior M41, M42
Females 23.2
Fentanyl 10.2, 49.5, M179, T41, T192, W178
Fetal exposures of alcohol and other drugs M11
FFA M117
Fiber photometry 5.2, M40, M186, T52, T127
Fibroblasts W163
First episode psychosis T144, W127
FKBP5 ..... M71, W78
Flanker task M196
Fluoxetine M90, T18
Functional MRI (fMRI) 5.3, 12, 13.2, 27.3, 38.3, 38.5, 41.4, 42.3, 45, 45.3, 47.4, M4, M19, M23, M60, M122, M131, M154, M164, T3, T6, T21, T56, T60, T61, T70, T76, T87, T200, W25, W46, W67, W114, W117, W158, W186, W192, W195, W198
fMRI effective Connectivity M103, T5
fMRI faces paradigm M103
fMRI functional connectivity T62, T78, W173
Focused ultrasound 19.4
Food cues W46
Forced swim test W29
Four-core genotype mouse W179
Fractional amplitude of low frequency fluctuations M61
Fragile X syndrome T80, W23
FreeSurfer M72, T131
Frontolimbic network M14
Frontoparietal network W4
Frontostriatal circuitry W33
Fronto-striatal networks M61
Frustrative non-reward 5.2, 5.3
Functional capacity M114
Functional connectivity M96, W47
Functional magnetic resonance spectroscopy T69
Functional near-infrared spectroscopy T182
Functional neuroimaging M56, W164
Functional variants T23
Functioning W121
G9a W180
GABA 45, M128, T153, T190, W2, W5
GABA neuron M133
GABA-A receptors M28, M75, T199
GABAergic interneurons 48, 48.3, T63, W18, W98
GAD M17
Galanin W144
Gamma 6.4, 24.2
Gamma oscillation 24, M188, W196
GAT-3 ..... T166
Gender differences M74
Gene co-expression networks 37
Gene expression 32, 32.3, 52.1, M45, M148, M200, T16, T60
Gene-by-sex interaction 37.5
Gene-prioritization 20.3
Generalized anxiety disorder T73
Genetic association 25
Genetic association study 2
Genetic human model T13
Genetic risk factor W72
Genetic variability M19
Genetics 2.2, 37.5
Genetics of depression T23
Genome-wide association studies T140
Genomics 2.4, M121, W123, W124
Genotypes T100
Geriatric M78
Ghrelin T179
Glia 3.1
Globus pallidus 9.4, T131, W152
GLT-1 ..... T163
Glucocorticoid receptor W78
Glucocorticoids W80
GluN2B M89
Glutamate 15.3, 43.2, M128, M185, M191, T145, T147, T175, T176, W5, W45
Glutamate GABA M145

Glutamate receptor function M94
Glutamate transporter (EAAT3) M101
Glycine transporter 1 inhibitor T135
Glyoxalase 1 ..... W162
Goal-directed behaviors M135, T63, W193
Gonadal Hormones M48, W179
GPCRs 32.2
GPER1 ..... T193
Graph theory M66, T88
Graph-based analysis W106
Grey matter morphometry M159
Guanfacine W22
Gut microbiome 29.2, 29.3, W130, W167
Gut microbiota W168
Gut-brain axis 7.3
GWAS 2.1, 20.2, 20.3, T174, W31, W102, W123
Habenula 28, 36.2
Habit W152
Habit formation 48.4
Hallucinations 6, 6.3, M129, M130
Hallucinogen W200
Handwriting M125
Harm avoidance 39.4
HCN M50
HDAC5 ..... T162
Headache 32.5, 47.5
HEAL initiative W1
Health disparities 51.1, 51.4, T82, T183
Health promotion W12
Healthy controls M46
Heart rate variability 29.4, M14
Heritability M67, M70, M121
Heroin T40, W188
Heroin self-administration M184
Herpesvirus M97
Heterochromatin 25.3
Hierarchical perceptual inference W122
High fat diet M45
High potency THC M174
Hippocampal function W131
Hippocampal shape W133
Hippocampal subfields T77
Hippocampus 38.2, 38.3, M81, M84, M90, M117, T3, T154, W5, W19, W78, W79, W133, W137
Histone acetylation M149
Homeostatic plasticity M53
Homeostatic synaptic transmission W145
Hopelessness M60, W84
Horizontal pleiotropy 54.2
Housing M177
HPA axis T7, W78, W80
Human genetics M97
Human laboratory study T179
Human neuroimaging 13, T96, T101, T177, T180, T198, W70, W75, W76, W133, W191, W193
Human post-mortem brain 49.5, 54, M120
Human postmortem brain tissue M106
Humans T108
Hybrid PET/MR W166
Hydroxynorketamine T112
Hyperarousal 14.3, M13
Hyperlocomotion M127
Hypocretin 28
Hypothalamic-pituitary-adrenal axis W197
Hypothalamus T17
Ibudilast T42
Illness trajectory M199, T154
Immobility 32.4
Immune biomarkers 51.4, M165, T146
Immune function 3.4
Immune responses 3, 29.4, 51.4
Implicit bias 35
Implicit priming W46
Impulse control 9.2, M47
Impulsivity 9, 11, M46, M173, T8, T83, T169, T178, W52, W154, W186
In vivo calcium imaging 46.1, M104, T53, T54, W183
In vivo microscopy M102
Incentive motivation 10.1, T54, W189
Incentive salience M187, W184, W186
Incubation of drug craving 36.5, M142, M156
Individual differences M187, W70
Individual variation M172
Induced pluripotent stem cells (iPSCs) 20, 52.4
Infancy 13, 13.1, 26, 26.2, 26.3
Infant 26.4, W27
Inference 6
Inflammasome M2, W38
Inflammation 15, 15.3, 15.5, 23, 23.2, 23.3, 23.4, 23.5, 30, 30.2, 36.3, M38, T64, T72, T103, W9, W57, W129, W130
Inflammatory cytokines W81
Inflammatory markers T102
Information encoding M190
Inhibitory control T27
Inhibitory interneurons T126
Insomnia 20.3, 28.1, M137, M139, T97, T99, T116, T157, W92
Instrumental learning 39.3
Insula M115, M163, W117
Insular cortex T130
Insulin 30.3, W45
Insulin resistance 30.4, M74
Intergenerational depression M59
Interleukin-8 ..... T24
Internal capsule 46.1
Internalizing behavior 13.1, T79
Internalizing disorders T8
Internet of things W48
Internet survey W160
Interneuron 24.2, 48.2
Interoception T73
Interpretation bias T22
Intracortical myelin W110, W118
Intracranial self-stimulation T47
Intravenous drug self-administration T48, T187, W178

Intrinsic excitability W184
Intrinsic functional connectivity W67
Intrinsic neural timescale W122
Ion channels M49, T52
iPSC W54
Irritability 5.3, 5.5, M4, T27, W199
Irritability/Aggression 5, 5.2, 5.4, 28.2, W50
IV—ketamine W88, W95
Juvenile critical period 24.3
Juvenile social isolation M1
Kappa agonist W180
Kappa opioid receptor antagonist T47
Kappa opioid receptors T171, T189, W157
Ketamine 16, 41.5, 47.3, M55, M57, M82, M86, M87, M130, T18, T112, T114, T115, W19
Ketogenic diet W151
Ketorolac M82
Kinases T39
Kynurenic acid T160
Kynurenine pathway M64, T160
Kynurenines 15.3
L1 retrotransposons 25.2
Language delay T121
Large scale networks 45
Late life depression W95
Late-life depression W71
Latent factor analysis T27, T61
Lateral habenula 28.2, M192
Lateral hypothalamus M5
Lateral inhibition T138
Lateral orbitofrontal cortex M104, M135
Lateral septum M20, M43
Learning M16
Learning and memory M42, M95, W5, W194
Learning theory T2
Lemborexant M139, T157
Leptin M74
Lesion W75
Leukocyte telomere length M38
Lifetime stress 29, T82
Limbic brain circuitry 37
Liquid chromatography/mass spectrometry 10.3, M171
Lithium M38, W54
Lithium response W94
Liver brain axis T176
Local field potentials W49
Locus coeruleus 49.3, T173
Long access self-administration T47
Long noncoding RNA 37.2
Long-acting injectable M125
Longitudinal W34
Longitudinal analysis M9, M117
Longitudinal imaging 38.3
Longitudinal MRI M81
Longitudinal studies 38
Longitudinal study 14.4, M199
Long-term depression W190
Long-term potentiation 32.4, T34
Loss W56
LSD 47.3, W49
LSD microdosing T108, W61
M1 and M4 muscarinic receptors M110
Machine learning M100, M121, T30, T59, T181, W49, W71, W155
Machine learning classification 42.5, M67
Magnesium W2
Magnetic resonance imaging 47, W137
Magnetic resonance spectroscopy M21, T67, T143, T145
Magnetic seizure therapy T25, T92
Major depression 37.5, 46.4, M54, W82
Major depressive disorder (MDD) 3.4, 5.5, M56, M57, M74, M92, M93, T23, T24, T25, T92, T93, T94, T95, T104, T117, W57, W59, W60, W67, W68, W70, W74, W199
Major depressive episode 15, 15.2
Mania 38.5, W50
Marijuana M158
Maternal behavior M15, W158
Maternal brain W158
Maternal depression 29.3, T167
Maternal immune activation 25.4
MATRICS consensus cognition battery (MCCB) T137
Matrix metalloproteinase-9 (MMP-9) M144, W14, W137
MCH neurons 49.4
MDD 2
MDMA W6
MDPV self-administration W175
MeCP2 ..... W102
Medial orbitofrontal cortex T53
Medial prefrontal cortex 14.2, 24, 24.1, 24.3, 48.3, M42, T40, T65, T85, T156, W140
Medial septum M155
Medication adherence 18
Medication assisted treatment 11
Medication development 7.3
Medio-dorsal thalamus T53
Medium spiny neuron M49, M146, M150, M190, T41, W183
Memantine W100
Memory 36.4, W104
Memory and learning M143, T66
Memory encoding and retrieval W18
Memory reconsolidation 41.5, W187
Mendelian randomization 54.2
Menopause 3.3
Mental disorders W42
Mesocorticolimbic system T87
Mesolimbic reward circuitry 34.5, T51, W194
Meta-analysis 42.4, M64, T37, T143, T197, W86
Metabolic biomarker T177
Metabolic defect W129
Metabolism 23, 23.4, 23.5, T159, W167
Metabolomics 7.4, 29.3, M168, W168
Metabotropic glutamate receptor 5 (mglu5) T175
Methamphetamine M161

Methods 1
mGlu receptors 48.3
mGlu5 ..... M191
mGlu5-NAM M182
mGluR5 receptors T127, W40
Mice 49.2
Microaggression 35
Microbiome 29, 51.4, M168
Microbiota-gut-brain axis M77
Microglia 29.2, M30, M33, M34, T64, T120
Microglia engulfment 43.4, W159
Microglia priming M76
Microglial activation 15.2
Microresistance 35
MicroRNA 39.1, T131, T141
Mifepristone 7.5
Migraine 47.5
Mild traumatic brain injury M7
Mindfulness M25
Mineralocorticoid receptor M167, W78
Miniscope 52, T119
Mismatch negativity 6.5
Mitochondria 23.3, 54, 54.2, 54.5, M33, M45, T112, W57
Mitochondrial DNA 54, W126
Mitochondrial dynamics W57
Mitophagy W57
Mobile DNA 25
Molecular genetics 2.1, M37, T124
Molecular imaging 19.3
Monetary incentive delay task M63, T61
Monetary reward M8, T87, W172
Monoamines M47
Monocytes W108
Monogamy T119
Mood 28, M70, T108
Mood and anxiety disorders 3, 38, T98, T107
Mood disorders 42.2, 44, M64, M83, M88, M89, T16
Morphometry M115
Motivation M48, M62, M180, W185, W194
Motor activity M67
Motor behavior T86
Motor evoked potentials T199
Mouse T81
Mouse behavior M127
Mouse genetics 32.3
mPFC M95, M100, T162
MRI 26.4, 42, 45.4, M66, T1, T186, W64
MRS W107
MRSI M128
Multimodal data 42.5
Multimodal neuroimaging T1, W121, W151
Multi-omics M168, W8, W56
Multiplex families 2.2
Multi-site MRI 31.3
Mu-opioid receptors 32.5, T28, T50, T171
Muscarinic acetylcholine receptor M88, W53
Muscarinic receptors T150
Myelination M30
Myosin M143
N,N-dimethyltryptamine (DMT) T58
N100 ..... W119
N-acetylaspartate T122
N-acetylcysteine T145
NAD+ and NADH W98
Naltrexone T151
Nanoparticles 19.4
Natural dietary product W160
Natural language processing (NLP) W120
Natural setting T58
N-back T182
Negative emotionality T195
Negative reinforcement 34.4
Negative symptoms 21, M108, T136, W121, W129
Neonates 13.2
Network based statistic (NBS) T31
Neural circuitry 5
Neural circuit and animal behavior 10.4, 52.1, 52.3, M44, T51
Neural circuits 34.2, 41.2, M136
Neural decoding 19.5
Neural modelling W69
Neural network connectivity W69
Neural oscillations 24.1
Neural predictors T30, T88
Neurocircuitry W149
Neurocircuits 10, 19.2
Neurodevelopment 20.4, 38, 41.3, 45.4, 55, T59
Neurodevelopmental and behavioral deficits M11
Neurodevelopmental disorders 2, 26, W32, W108
Neuroeconomics W114
Neuroendocrine T71
Neuroepigenetic editing W7
Neuroepithelium 36
Neurofibromatosis type 1 ..... M29
Neurogenetics 2.3
Neuroimaging 26, W34
Neuroimaging biomarkers 30
Neuroimmune T120
Neuroimmune interaction T180
Neuroimmune mechanisms M169, M185, T42, T45, T184, W167
Neuroinflammation 15.4, M99, T24, T145
Neuromelanin M8
Neuromelanin-sensitive MRI M13, T173, W153
Neurometabolism W136
Neuromodulation 19, 19.5
Neuromodulators 19.3
Neuronal ensemble 52, 52.1, 52.3, W143
Neuronal epigenome 25.3
Neuronal tracing T74, W190
Neuropathic pain 32, 32.3, M97, M148, T125
Neuropeptides M176, T118
Neuropharmacology 48.3, W88
Neurophysiology 46.3

Neuroplasticity 47, 47.2, 51.2, T121, W61, W107
Neuroplasticity hypothesis M93
Neuropsychiatric disorders [schizophrenia, Parkinson's disease, major depressive disorder] 37.4, 46.3
Neuropsychology M78
Neuropsychopharmacology 19.4, 41.4
Neurosteroids T190
Neurostimulation 19
Neurotechnology 19.2
Neurotensin M43, T118
Next generation sequencing M148
N-glycosylation T36
Nicotine 36.2, M39, M153, M181, M183, W177
Nicotine addiction M151, W148
Nicotine demand M166
Nicotine dependence M170, W138
Nicotine vapor M170
Nicotine withdrawal W171
Nicotinic acetylcholine receptors W53
NMDA antagonists M130
NMDA glutamate receptors T40
NMDA Receptor M53, M118, M133, T199
NMDA receptor antagonist T106
NMDA receptors T146
NMDA receptors, MMN, ERP, auditory, training 6.4
NMDAR hypofunction M118
Non pharmacological interventions M79, T133
Non-coding RNA W147
Nonhuman primate model T83
Nonhuman primate models W168
Non-invasive brain stimulation T133
Non-invasive neuromodulation W170
Non-suicidal self-injurious behavior M65, T140
Non-suicidal self-injury (NSSI) T83
Noradrenaline M13, T156
Noradrenergic W144
Norepinephrine 14.2, T173, W22
Nosology 42.2
Novel antidepressant T65
Novel therapeutics 53, T185
Novelty response W22
Npas4 ....W145
NR2B receptor M89
NREM EEG gamma power M132
Nuclear factor kappa B T184
Nucleus accumbens 5.2, 9.2, 10, 10.2, 10.3, 34.3, 36.5, M3, M49, M144, M150, M162, M186, M188, M201, T41, T107, T119, T127, T165, T178, W14, W28, W55, W66, W145, W169, W183, W184, W185, W188, W189
Nucleus accumbens core W140
Nucleus accumbens shell 10.1, M146, T54
Nucleus reuniens W13
Number needed to treat W91
Obesity M37, T68, W46
Obsessive-compulsive disorder (OCD) 45.3, 46, 46.1, 46.2, M101, M102, M163, T31, T128, T129
Obsessive-compulsive spectrum disorders (OCDS) T127
Occipital pole M117
OCD T130
Olanzapine M111
Oleanolic acid acrylate T28
Oligodendrocytes 36
Omega-3 fatty acids W197
Operant behavior T181, T191
Opiate addiction W170
Opioid M99
Opioid abuse M172, M189, T192, W40
Opioid addiction 9.1, 34.3, 49.2, M144, M162, T38, T44, T50, T170, T171, T196, W140, W144, W159, W161, W188
Opioid dependence M148, T38
Opioid epidemic 50
Opioid epidemic—novel approaches W164
Opioid peptides M171
Opioid receptors T151
Opioid side-effects T45
Opioid use disorder T45, W153, W155, W158, W160, W164
Opioid withdrawal T171, W144
Opioids 7.4, 10, 32, 49.5, T48, W178
Opto-chemogenetics 52.2
Optogenetics 32.4, 41.2, M40, M100, M187, W20, W48
Orbitofrontal cortex (OFC) M59, T53, T130, T196, W141
Orexin 28.1, 28.3, T188
Orexin receptor antagonist 28, 28.2, W60
Orexin system W134
Organic cation transporters M147
Oscillation 6.4
Oscillations 48.5
Oxidative phosphorylation 54.4
Oxidative stress T67, W58
Oxycodone 9.1, 32.3, M142, T47, T187
Oxytocin W24, W26
Oxytocin and addiction 7.2
Oxytocin receptor 7.2
PACAP 32.5, M138
Pain 32.2, 32.5, 53, M175, T161, W1, W199
Pain analgesia M99, T45
Pain therapeutics W170
Paliperidone palmitate long-acting injection W110
Paranoia 6, 6.2
Paraventricular nucleus of the thalamus W134
Parenting distress M59, T167
Parkinsonism 45.2, 45.4
Parkinson's disease 9.4, 46, M98
Partial agonist ligands T49
Parvalbumin 24.2, 48.2
Parvalbumin fast-spiking GABAergic interneurons 48.4, 48.5, M118
Patch foraging W153
Pathways T142
Patient outcomes W62, W86
Patient reported outcomes M137, T95
Pavlovian bias 39.3
Pavlovian conditioning M19, T9, T53, W184
Pediatric T128

Pediatric irritability W36
Pediatric PTSD 38.3
Pediatrics 38.4, W35
Perceived stress M173
Perceptual reasoning T77
Periaqueductal grey (PAG) 32.4
Perinatal T111
Perinatal stress 29, 29.4, M11
Perineuronal nets 36.4
Peripheral biomarker T90
Persistent avoidance T130
Personality T76
Personalized medicine 12.3, 46.4, 47.3
Positron emission tomography (PET) 15.2, 15.5, 43.3, M191, W157
Positron emission tomography (PET) Imaging 15.4, 43.5, T7, W32, W96, W165, W171, W173
PET imaging study M73, W40
PharmacoBOLD M105
Pharmacogenetics W73
Pharmacoepidemiology W73
Pharmacogenetics M69
Pharmacogenomic-guided treatment recommendations W73, W74
Pharmacogenomics T100
Pharmacologically-based nomenclature 18
Pharmacology 18
Pharmacotherapy 41.4, M148, T38
Phosphodiesterase-4 (PDE4) W104
Phosphoproteomics T39, W8
Phosphorylation W146
Physical activity W43
Physician-scientist 33
Physiologic biomarkers M91
Pimavanserin M129, T136, W59
Place cell W131
Placebo response M63, W76
Placebo-controlled trial W128
Plasma membrane monoamine transporter W176
Plasma psilocin W77
Pleiotropy analysis W123
Polydrug use M143
Polygenic risk scores W31, W32
Polygenic scores T35
Polysomnography T26, T158, W96
Positive emotion W84
Postmortem W125
Postmortem brain tissue 37.3, 54.4, T33, T179, W124
Postmortem human brain 37.4
Postpartum anxiety M80
Postpartum depression M80, T109, W80, W81, W91, W92
Prader Willi syndrome W24
Prairie vole T119
Pramipexole M56
Prebiotic treatment in schizophrenia W112
Precision medicine for mood and anxiety disorders 29.4
Precision medicine for mood disorders 29, 55
Precision psychiatry M56
Preclinical models and endpoints W1
Prediction 26.3
Predictive coding 6.2, T155
Predictive models 20.2
Predictor of treatment response W71
Prefrontal 24.2
Prefrontal circuit M119, T19
Prefrontal circuit maturation 24, M12
Prefrontal cortex 41.2, M34, M90, M135, T120, T182, W21, W30, W53, W63, W192
Pregnancy 51.2, T111, W27, W98
Prelimbic cortex M135, M160, T130
Premenstrual dysphoric disorder M73, M75
Prenatal drug exposure M161, W159
Prenatal stress 29.2
Prescription opioids M142, T38
Presymptomatic 26.4
Presynaptic mRNA T66
Probabilistic reversal learning 41.3, M126, M195, W200
Prodromal schizophrenia W119
Prodrome 12
Progesterone T4
Pro-inflammatory cytokines T123, W82
Proof of concept M25
Proopiomelanocortin neurons T194
Prophylactic M178
Propranolol M6
Protein aggregation T32
Proteomics 41.3, 54.5, W124, W146
Psilocybin 47.5, M41, M140, T46, T129, W77, W97
Psychedelic medicine 47, M140, T46
Psychedelics 16, 47.2, 47.3, 47.4, 47.5, M41, M85, T62, T108, T129, W49, W99
PsychENCODE 25.3
Psychiatric disease 25
Psychiatric education 33, W44
Psychiatric genetics 5.4, 20, T174
Psychological effects T58
Psychological pain T99
Psychomotor speed W174
Psychomotor symptoms 45.1
Psychoneuroimmunology T180
Psychopharmacology treatment guidelines W90
Psychophysiology 14.4, W17
Psychosis 6.2, 30.4, 42.2, 54, M113, M115, M131, T132, T146, T152, W35, W116, W122, W137, W198
Psychosis continuum 6.2
Psychosis spectrum M122
Psychosis spectrum disorders 47.3
Psychostimulants W25
Psychotherapy T5, T167
Psychotic depression W128
Psychotic disorders 42
Psychotic-like experiences M98

Psychotropic medications 18, T139, W42
Post traumatic stress disorder (PTSD) 2, 2.1, 14.3, 14.4, 14.5, 23.5, 37.3, 51, 51.1, M2, M3, M10, M13, M14, M17, T3, T4, T5, T7, T72, T167, W9, W10, W12, W13, W14, W16, W63, W134
Pubertal stress M85, W89
Puberty T71
Public health T168
Punishment T170
Pupillometry 14
Pyramidal neuron 54.4
qFISH M38
QIDS-SR16 ..... W68
Quality of life T183
Quantitative EEG M140
Quantitative electroencephalography (qEEG) M182
Quetiapine M98, T24
R-(-)-ketamine T115
Racial differences W82
Racism 51, 51.1, T10
Raclopride M63, M96
Randomized clinical trial T5, T136
Randomized controlled trial 7.5
Rapid antidepressant M53, M84
Rapid mood screener W87
Rapid-acting antidepressant T115
Ras/MAPK pathway T13
RASopathies M29
Rats W20
RCT M69
Real-time fMRI W64
Real-time fMRI neurofeedback M25, W84, W85, W194
Receptor binding T28
Receptor internalization, trafficking W166
Recidivism M36
Recordings W20
Recovery 22
Redox dysregulation 54.3
Reelin M87
Registry T111
Regulatory policy 16
Regulatory variation 20.4
Reinforcement M188
Reinforcement learning 44, M16, W192
Reinforcement learning modelling M195
Reinforcement-based decision-making T191
Reinstatement M166, M177, T170
Relapse T29
REM sleep 49.4, M138, M159, T160
Remission 38.3
Remote memory W30
Repetitive behavior W24
Repetitive transcranial magnetic stimulation (rTMS) M21, M35, M91, T90, T199, W63, W86
Reproduction M48
Research domain criteria (RDoC) 55, T59
Residency training 33
Residential treatment 39.4
Resilience 34.4, M197
Resiliency M172
Respiration T112
Resting state 38.5, W116
Resting state functional connectivity 12.2, 13.4, M123, M130, T13, T56, T59, W25, W106, W138
Resting state intrinsic connectivity T55
Resting-state fMRI 6.5, 45.2, M65, M191, T5, T31, T128, W39, W77, W120, W127
Retina 49.3
Retrotransposon 25.4
Reversal learning T80
Reward 27, 27.1, 49, M63, M153, M158, T76, W20, W28, W156
Reward and aversion M145
Reward anticipation T177
Reward circuitry 34, 34.3, 46, M162, W143
Reward functioning M61
Reward learning M161, M190
Reward memory W97
Reward neural circuitry 38.5, W67
Reward sensitivity W52
Reward-based decision-making 39.3, M62, T191, W153
Reward-seeking behavior M84, W115, W139
Rhesus M18
Risk and resilience 38.5, 39.1, M9, M11, W121
Risk calculator 12.1, 12.3
Risk taking behaviors W141
RNA splicing W147
RNAseq 10, 10.2, 49.4, T16, T18, T41, T107, T142, T156, W8, W56, W79
Rodent models 6.3, M62, T47, W11
Rosuvastatin T94
Rumination T56
Safety 39.2
Salience 27.1
Salience network 13.4, T31
Salvinorin A T62
Samidorphan M111, T151
Schizoaffective disorder W112
Schizophrenia (SCZ) 2.2, 6.3, 25.2, 37, 42.3, 43, 43.4, 45.1, 45.2, 45.3, 45.4, 48.2, 54.3, 54.4, M64, M106, M107, M108, M111, M114, M117, M118, M120, M122, M124, M125, M126, M128, M134, M136, M200, T25, T32, T33, T34, T36, T104, T134, T135, T136, T138, T139, T141, T143, T145, T146, T148, T150, T153, T154, T160, W110, W112, W114, W118, W121, W122, W123, W124, W125, W126, W129, W133, W134, W136, W138
Schizophrenia and bipolar disorders 37.5, T140
Schizophrenia negative symptoms 42.4
Schizophrenia novel treatment 43.2, M71, T133, T137, T142, W130
Schizophrenia prodrome 8
Schizophrenia spectrum disorders 30, T197
Schizophrenia subtypes 43.5, M116, T32
Schizophrenia, antipsychotics 43.3, M110, T35, T37
Schizophrenia, synaptic aberrations 6.5, 48, M200
Schizophrenia; functional capacity; technology W132
Schizophrenia; technology 42.4
Schizophrenia-like behavior W135

Scopolamine M88
Screening W87
Seahorse T112
Self-administration 41.4, M177, T50, W51, W148, W177, W187
Self-regulation W194
Seltorexant W60
Sensorimotor M23, T86
Septum 36.2
Sequencing M120
Serious mental illness 4
Serotonin 3.2, M180, T91, T189, W6, W52, W89
Serotonin 1b receptor W52
Serotonin 5-HT2A receptor 47.4, M85, W200
Serotonin 5-HT2C receptor M192
Serotonin transporter M73
Serotonin transporter genotype T83
SERT W6
Serum levels M92
Set shifting 24.2
Severe major depressive disorder W62
Sex 23.3
Sex chromosomes W179
Sex differences 3, 3.1, 3.4, 23, 24.4, 27, 27.1, 27.2, 27.3, 34, 34.5, 37.2, 37.4, 37.5, M16, M30, M32, M44, M94, M147, M189, T12, T67, T68, T71, T79, T96, T123, T164, T178, T181, T187, T193, W7, W39, W55, W79, W89, W142, W146, W157, W173, W178, W179, W188
Sex hormones 2.1, T67, W142
Sexual dimorphism 34.2, 36.3
SGE-516 ..... T190
Shank3 ..... T40
Shati/Nat8l M95
Short tandem repeat M120
Side effects W42
Sigma-1 receptor T161
Signal detection T169
Sign-tracking M151
Simulated data 42.5
Simulated driving T168
Simultaneous PET-MR M96
Single-cell analysis 51.4
Single-cell RNA sequencing 20.5, 36, W109, W148
Skin conductance response T44, T57, W16
SLC39A8 ..... T36
Sleep 49, M67, M70, M138, M189, T99, T116, T152, T159
Sleep architecture M132, M140
Sleep deprivation T26
Sleep disturbance 49.2, M27, M132, T97
Slow wave sleep M159, T26
Smartphone W48
Smartphone apps W164
Smoking M153, W154
Smoking cessation W177
SMS text messaging M109
SNRI M72
Sociability W41
Social anxiety M8, T71
Social attention T169
Social behavior 24, 24.3, 24.4, 40, M32, M34, M100, M141, T84, T123
Social brain M153
Social cognition T197
Social communication T78
Social defeat 40
Social defeat stress 10.2, M52, M76, T192
Social dominance T91
Social factors and functioning T180
Social functioning 31.1
Social interaction M28, M161
Social isolation 24.3, M34, W43, W115
Social media monitoring W160
Social motivation M51, M96
Social processing T169
Social recognition memory M20, M32
Social rejection M8
Social responsiveness M22
Social withdrawal T107
Socio-economic status M26, T10
Somatic mosaicisms 25.4
Somatostatin 48.2
Speed of processing W118
Sphingosine 1-phosphate receptor T125
Sphingosine-1-phosphate W105
Spironolactone M167
Src family kinases M87
Selective serotonin reuptake inhibitors (SSRIs) M11, M72, T70, W93
SSRT M154
Statistical methods W86
Stem cells T142, W108
Stimulants W37, W173
Strategy switching M155
Stress 23.3, 32.3, 52.1, M70, M86, T120, W19, W27
Stress and anxiety behavior 14.5, M176, W197
Stress and anxiety disorders M11, M116
Stress and depression 3.1, T60
Stress and trauma 23, 23.2, 51.3, M17, M24, T82, W21
Stress coping M197, W13
Stress models 24.4, 34.5, 36.3, W180
Stress reactivity M131, M169, T60, W165
Stress resilience and susceptibility M12, M194, T30
Stress-induced dopamine release T171
Striatal dopamine signaling T63
Striatum 6.3, 9.3, 10.4, M8, M102, T9, T158, W125
Structural and functional connectivity 13.3
Structural MRI 5.4, 45.2, M12, T15, T154, W120
Structural neuroimaging 12.4
Structure of psychopathology 55
Subcallosal cingulate W83
Subcortical shape analysis M26
Subcortical-cortical motor loops 45.1
Subgenual anterior cingulate T16
Substance abuse M123
Substance abuse disorders 22, 39.4, T167, T174
Substance use disorders 50, M3, T48, T169, T178, W186, W199

Substantia nigra T50
SUD-like phenotypes W175
Suicidal behavior M65, T140
Suicidal ideation M65, T93, T95, T99, T140
Suicidality 5, 5.5, M60
Suicide T99, T116, W84
Suicide prediction 5.5
Sulforaphane M22, T137
Susceptibility 34.4
SV2A protein 43.3
Symptom trajectory M9
Synapse T120
Synapse pruning 43.4
Synapses 43.2
Synaptic aberrations 32.3, 48
Synaptic density 43
Synaptic function W99
Synaptic plasticity 10.3, 32.3, 48.3, 52.1, M3, M15, T199
Synchrony T30
Synthetic psychoactive cathinones W175
Systematic review T197
Systemic inflammation W198
Systems biology 29.3
Systems neuroscience 14, W148
TAAR1 ..... M108, T149, W6
Target engagement W26
Task-based functional connectivity T78, W11
TBI T79, W106
TDCS W10
Temperament T84
Temporal discrimination W131
Testosterone T65, T71
Tetrapartite synapse M3, M144
Thalamus 24.3, M130
THC M174
Th-Cre M187
Theta 6.4
Theta burst transcranial magnetic stimulation M10
Theta-burst stimulation M14
Time cell W131
Time-frequency 6.4
Timing M188
TMS T101
TMS-EEG T153, W107
Tobacco smoking W171
Tolerance W174
Top-down W196
Top-down control M119
Touchscreen M196, T156, W115
Training 1
Transcriptome 20.2, T141
Transcriptomics 14.5, 37.3, T66, W8, W109
Transdiagnostic 5, M199, M200, W191
Transforming growth factor beta-1 ..... T115
Transgenerational M15
Transgenerational epigenetic effects M11
Transgenic mice M133, W4, W104, W162
Transgenic models M194
Translating innovation 53
Translational approaches to drug development 7
Translational neuroscience 5, 9.2, 19.2, 22, 28.3, W181
Translational pharmacology M167
Translational research T6, T108
Translatomics W8
Trauma W17
Trauma exposure T1, T69
Traumatic brain injury 15.2
Treatment M79, W160
Treatment adherence M109, W155
Treatment mechanisms 7
Treatment outcome prediction T88, W155
Treatment prediction W70
Treatment resistant depression 3.2, M68, T18, T90, T116, W85
Treatment response 42.5
Treatment-refractory depression W95
Treatment-resistant schizophrenia M112
Treatment-response M55
TRIP8b M50
TrkB M20, W169
Tryptophan catabolites (TRYCAT) M92, T160
TSPO 43, 43.5
TSPO and [11C]PBR-28 PET 43.3, M165, T7, T45
Two-photon calcium imaging T126, T155
Two-photon imaging 14.2
Type 1 corticotropin releasing factor receptor M1
Type-2 diabetes 30.4
Ultra high-risk youth 8
Ultrasonic vocalization W11
Uncertainty W189
Underrepresented 35
V1aduct W101
Vagus nerve M77
Valence 27.1, T118
Validation 40, W1
VANILLA W101
Vaping M179
Vapor W135
Vascular endothelial growth factor T90
Ventral attention network T6, T31
Ventral capsule/ventral striatum 9.3
Ventral hippocampus 39.2, M136, T14, T74, W66
Ventral pallidum 9.1, 52.2, M145, T166
Ventral tegmental area (VTA) 27.2, 32.4, M52, M186, T52
Ventromedial prefrontal cortex T73, W84
Verbal learning T137
Veterans W63, W106
Violence T139
Visual attention M119
Visual cortex 14.5, M119, T126
Visual processing M103
Visuospatial ability T121
Visuospatial working memory T137, T138

vmPFC W10
Voltage-gated calcium channel M193
Voxel-based morphometry (VBM) M163
Vulnerability M172, W66
Vulnerability traits 23.4
White matter fractional anisotropy M46
White matter integrity W9
Whole-brain rodent imaging 7.4, W3
Whole-cell patch clamp recording W184
Whole-genome M120
Wistar Kyoto rat M140
Withdrawal M39, M148, M170, M189, T38
Women's health T111
Women's mental health W93
Working memory 48.2, M157, T20, T69, T182
Worry T56
Xanomeline T150
Youth M4, M199
Zebrafish M31, W69
Zuranolone T109, W91
α5-GABAA receptor negative allosteric modulator M84